Peter Borchmann
1st Department of Medicine, Cologne University Hospital · University Hospital of Cologne · University of Cologne
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Peter Borchmann as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 19:06 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06045195 · Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin LymphomaUniversity of Cologne · not yet recruiting · Hodgkin Lymphoma · principal investigator
- Ph2NCT04844866 · Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma PatientsMiltenyi Biomedicine GmbH · recruiting · Diffuse Large B-cell Lymphoma · principal investigator
- N/ANCT03968250 · CBT on Fatigue in Survivors of Hodgkin LymphomaUniversity of Leipzig · completed · Hodgkin Lymphoma, Fatigue · principal investigator
- Early Ph1NCT03893019 · MB-CART20.1 MelanomaMiltenyi Biomedicine GmbH · terminated · Melanoma (Skin) · principal investigator
- Ph1NCT03870945 · Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1)Miltenyi Biomedicine GmbH · completed · B-cell Non Hodgkin Lymphoma · principal investigator
- Ph1/Ph2NCT03664635 · MB-CART20.1 LymphomaMiltenyi Biomedicine GmbH · completed · Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, B-cell Lymphoma Refractory · principal investigator
- Ph3NCT02661503 · HD21 for Advanced StagesUniversity of Cologne · unknown · Classical Hodgkin Lymphoma · principal investigator
- Ph2NCT02191930 · Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin LymphomaUniversity of Cologne · completed · Hodgkin Lymphoma · principal investigator
- Ph2NCT01569204 · Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin LymphomaUniversity of Cologne · completed · Hodgkin Lymphoma · principal investigator
- Ph1/Ph2NCT01453504 · Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin LymphomaUniversity of Cologne · completed · Hodgkin Lymphoma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 19:06 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 19:06 UTC. The ranking covers the 200 most relevant of 96 PubMed records, and a shared surname and initials can bring in a namesake. All 96 on PubMed
- 3,432 citationsRCR 128.5
- Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.N Engl J Med · 2010692 citationsRCR 17.4
- Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.J Clin Oncol · 2012566 citationsRCR 14.1
- 524 citationsRCR 26.6
- 459 citationsRCR 13.3
- Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.N Engl J Med · 2022459 citationsRCR 30.2
- 326 citationsRCR 8.5
- 298 citationsRCR 10.3
- 287 citationsRCR 7.8
- CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial.Nat Med · 2023271 citationsRCR 20.4